156 related articles for article (PubMed ID: 7662969)
1. Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice.
Boland EJ; Liu YC; Walter CA; Herbert DC; Weaker FJ; Odom MW; Jagadeeswaran P
Blood; 1995 Sep; 86(6):2198-205. PubMed ID: 7662969
[TBL] [Abstract][Full Text] [Related]
2. First case report of hemophilia B Leyden in Japan.
Yamashita A; Nagae C; Mori M; Ashikaga T; Kojima T; Taki M
Int J Hematol; 2017 Jul; 106(1):135-137. PubMed ID: 28168417
[TBL] [Abstract][Full Text] [Related]
3. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype).
Reitsma PH; Mandalaki T; Kasper CK; Bertina RM; Briët E
Blood; 1989 Feb; 73(3):743-6. PubMed ID: 2917196
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.
Vidaud D; Tartary M; Costa JM; Bahnak BR; Gispert-Sanchez S; Fressinaud E; Gazengel C; Meyer D; Goossens M; Lavergne JM
Hum Genet; 1993 Apr; 91(3):241-4. PubMed ID: 8478007
[TBL] [Abstract][Full Text] [Related]
5. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden.
Reijnen MJ; Sladek FM; Bertina RM; Reitsma PH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6300-3. PubMed ID: 1631121
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden.
Hirosawa S; Fahner JB; Salier JP; Wu CT; Lovrien EW; Kurachi K
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4421-5. PubMed ID: 2352926
[TBL] [Abstract][Full Text] [Related]
7. A single base pair deletion in the promoter region of the factor IX gene is associated with haemophilia B.
Hall AJ; Chuansumrit A; Peake IR; Winship PR
Thromb Haemost; 1994 Dec; 72(6):799-803. PubMed ID: 7740444
[TBL] [Abstract][Full Text] [Related]
8. The putative factor IX gene promoter in hemophilia B Leyden.
Reitsma PH; Bertina RM; Ploos van Amstel JK; Riemens A; Briët E
Blood; 1988 Sep; 72(3):1074-6. PubMed ID: 3416069
[TBL] [Abstract][Full Text] [Related]
9. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Zhang G; Shi Q; Fahs SA; Kuether EL; Walsh CE; Montgomery RR
Blood; 2010 Aug; 116(8):1235-43. PubMed ID: 20445020
[TBL] [Abstract][Full Text] [Related]
10. Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region.
Royle G; Van de Water NS; Berry E; Ockelford PA; Browett PJ
Br J Haematol; 1991 Feb; 77(2):191-4. PubMed ID: 2004020
[TBL] [Abstract][Full Text] [Related]
11. Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation.
Boccia LM; Lillicrap D; Newcombe K; Mueller CR
Mol Cell Biol; 1996 May; 16(5):1929-35. PubMed ID: 8628259
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter.
Reijnen MJ; Peerlinck K; Maasdam D; Bertina RM; Reitsma PH
Blood; 1993 Jul; 82(1):151-8. PubMed ID: 8324220
[TBL] [Abstract][Full Text] [Related]
13. A Chinese family with hemophilia B Leyden due to T-->A transition at position +6 of the FIX gene.
Chan V; Ha SY; Au P; Lam C; Chan TK
Am J Hematol; 2006 Apr; 81(4):300-1. PubMed ID: 16550516
[No Abstract] [Full Text] [Related]
14. Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene.
Reijnen MJ; Maasdam D; Bertina RM; Reitsma PH
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):341-8. PubMed ID: 8075306
[TBL] [Abstract][Full Text] [Related]
15. A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B.
Vielhaber E; Jacobson DP; Ketterling RP; Liu JZ; Sommer SS
Hum Mol Genet; 1993 Aug; 2(8):1309-10. PubMed ID: 8401514
[No Abstract] [Full Text] [Related]
16. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
[TBL] [Abstract][Full Text] [Related]
17. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
18. A less severe form of Haemophilia B Leyden.
Crossley M; Winship PR; Austen DE; Rizza CR; Brownlee GG
Nucleic Acids Res; 1990 Aug; 18(15):4633. PubMed ID: 2388855
[No Abstract] [Full Text] [Related]
19. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B.
Crossley M; Brownlee GG
Nature; 1990 May; 345(6274):444-6. PubMed ID: 2342576
[TBL] [Abstract][Full Text] [Related]
20. The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G; Gao M; Cao Q; Li W
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
